nach oben

Osteoporosis International

Erschienen in:

26.07.2021 | Review

Metabolomic biomarkers of low BMD: a systematic review

verfasst von: N. Panahi, B. Arjmand, A. Ostovar, E. Kouhestani, R. Heshmat, A. Soltani, B. Larijani

Erschienen in: Osteoporosis International | Ausgabe 12/2021

Einloggen, um Zugang zu erhalten

Abstract

Due to the metabolic nature of osteoporosis, this study was conducted to identify metabolomic studies investigating the metabolic profile of low bone mineral density (BMD) and osteoporosis. A comprehensive systematic literature search was conducted through PubMed, Web of Science, Scopus, and Embase databases up to April 08, 2020, to identify observational studies with cross-sectional or case-control designs investigating the metabolic profile of low BMD in adults using biofluid specimen via metabolomic platform. The quality assessment panel specified for the “omics”-based diagnostic research (QUADOMICS) tool was used to estimate the methodologic quality of the included studies. Ten untargeted and one targeted approach metabolomic studies investigating biomarkers in different biofluids through mass spectrometry or nuclear magnetic resonance platforms were included in the systematic review. Some metabolite panels, rather than individual metabolites, showed promising results in differentiating low BMD from normal. Candidate metabolites were of different categories including amino acids, followed by lipids and carbohydrates. Besides, certain pathways were suggested by some of the studies to be involved. This systematic review suggested that metabolic profiling could improve the diagnosis of low BMD. Despite valuable findings attained from each of these studies, there was great heterogeneity regarding the ethnicity and age of participants, samples, and the metabolomic platform. Further longitudinal studies are needed to validate the results and confirm the predictive role of metabolic profile on low BMD and fracture. It is also mandatory to address and minimize the heterogeneity in future studies by using reliable quantitative methods. Summary: Due to the metabolic nature of osteoporosis, researchers have considered metabolomic studies recently. This systematic review showed that metabolic profiling including different categories of metabolites could improve the diagnosis of low BMD. However, great heterogeneity was observed and it is mandatory to address and minimize the heterogeneity in future studies.

Nur mit Berechtigung zugänglich

Reginster J-Y, Burlet N (2006) Osteoporosis: a still increasing prevalence. Bone 38(2):4–9CrossRef

Svedbom A, Hernlund E, Ivergård M, Compston J, Cooper C, Stenmark J, McCloskey EV, Jönsson B, Kanis JA (2013) Osteoporosis in the European Union: a compendium of country-specific reports. Arch Osteoporos 8(1-2):137CrossRefPubMedPubMedCentral

Zhao Q, Shen H, Su KJ, Zhang JG, Tian Q, Zhao LJ, Qiu C, Zhang Q, Garrett TJ, Liu JW, Deng HW (2018) Metabolomic profiles associated with bone mineral density in US Caucasian women. Nutrition & Metabolism:15. https://doi.org/10.1186/s12986-018-0296-5

Wang J, Yan D, Zhao A, Hou X, Zheng X, Chen P, Bao Y, Jia W, Hu C, Zhang Z-L, Jia W (2019) Discovery of potential biomarkers for osteoporosis using LC-MS/MS metabolomic methods. Osteoporos Int 30(7):1491–1499. https://doi.org/10.1007/s00198-019-04892-0CrossRefPubMed

Johnson CH, Ivanisevic J, Siuzdak G (2016) Metabolomics: beyond biomarkers and towards mechanisms. Nat Rev Mol Cell Biol 17(7):451–459. https://doi.org/10.1038/nrm.2016.25CrossRefPubMedPubMedCentral

Beckonert O, Keun HC, Ebbels TM, Bundy J, Holmes E, Lindon JC, Nicholson JK (2007) Metabolic profiling, metabolomic and metabonomic procedures for NMR spectroscopy of urine, plasma, serum and tissue extracts. Nat Protoc 2(11):2692–2703. https://doi.org/10.1038/nprot.2007.376CrossRefPubMed

Qi H, Bao J, An G, Ouyang G, Zhang P, Wang C, Ying H, Ouyang P, Ma B, Zhang Q (2016) Association between the metabolome and bone mineral density in pre-and post-menopausal Chinese women using GC-MS. Mol BioSyst 12(7):2265–2275CrossRefPubMed

Lv H, Jiang F, Guan D, Lu C, Guo B, Chan C, Peng S, Liu B, Guo W, Zhu H, Xu X, Lu A, Zhang G (2016) Metabolomics and its application in the development of discovering biomarkers for osteoporosis research. Int J Mol Sci 17(12). https://doi.org/10.3390/ijms17122018

Xue L, Wang Y, Liu L, Zhao L, Han T, Zhang Q, Qin L (2011) A 1HNMR-based metabonomics study of postmenopausal osteoporosis and intervention effects of er-xian decoction in ovariectomized rats. Int J Mol Sci 12(11):7635–7651CrossRefPubMedPubMedCentral

10.

Ma B, Liu J, Zhang Q, Ying H, A J, Sun J, Wu D, Wang Y, Li J, Liu Y (2013) Metabolomic profiles delineate signature metabolic shifts during estrogen deficiency-induced bone loss in rat by GC-TOF/MS. PLoS One 8 (2):e54965. https://doi.org/10.1371/journal.pone.0054965

11.

You YS, Lin CY, Liang HJ, Lee SH, Tsai KS, Chiou JM, Chen YC, Tsao CK, Chen JH (2014) Association between the metabolome and low bone mineral density in Taiwanese women determined by 1H NMR spectroscopy. J Bone Miner Res 29(1):212–222CrossRefPubMed

12.

Miyamoto T, Hirayama A, Sato Y, Koboyashi T, Katsuyama E, Kanagawa H, Miyamoto H, Mori T, Yoshida S, Fujie A, Morita M, Watanabe R, Tando T, Miyamoto K, Tsuji T, Funayama A, Nakamura M, Matsumoto M, Soga T, Tomita M, Toyama Y (2017) A serum metabolomics-based profile in low bone mineral density postmenopausal women. Bone 95:1–4. https://doi.org/10.1016/j.bone.2016.10.027CrossRefPubMed

13.

Moayyeri A, Cheung CL, Tan KC, Morris JA, Cerani A, Mohney RP, Richards JB, Hammond C, Spector TD, Menni C (2018) Metabolomic pathways to osteoporosis in middle-aged women: a genome-metabolome-wide Mendelian randomization study. J Bone Miner Res 33(4):643–650CrossRefPubMed

14.

Pontes TA, Barbosa AD, Silva RD, Melo-Junior MR, Silva RO (2019) Osteopenia-osteoporosis discrimination in postmenopausal women by 1H NMR-based metabonomics. PLoS One 14(5):e0217348. https://doi.org/10.1371/journal.pone.0217348CrossRefPubMedPubMedCentral

15.

Cabrera D, Kruger M, Wolber FM, Roy NC, Totman JJ, Henry CJ, Cameron-Smith D, Fraser K (2018) Association of plasma lipids and polar metabolites with low bone mineral density in Singaporean-Chinese menopausal women: a pilot study. Int J Environ Res Public Health 15(5):1045CrossRefPubMedCentral

16.

Qiu C, Yu F, Su K, Zhao Q, Zhang L, Xu C, Hu W, Wang Z, Zhao L, Tian Q, Wang Y, Deng H, Shen H (2020) Multi-omics data integration for identifying osteoporosis biomarkers and their biological interaction and causal mechanisms. iScience 23(2):100847. https://doi.org/10.1016/j.isci.2020.100847CrossRefPubMedPubMedCentral

17.

Moher D, Liberati A, Tetzlaff J, Altman DG, Group P (2009) Preferred Reporting Items for Systematic Reviews and Meta-analyses: the PRISMA statement. PLoS Med 6(7):e1000097. https://doi.org/10.1371/journal.pmed.1000097CrossRefPubMedPubMedCentral

18.

Wishart DS, Knox C, Guo AC, Eisner R, Young N, Gautam B, Hau DD, Psychogios N, Dong E, Bouatra S, Mandal R, Sinelnikov I, Xia J, Jia L, Cruz JA, Lim E, Sobsey CA, Shrivastava S, Huang P, Liu P, Fang L, Peng J, Fradette R, Cheng D, Tzur D, Clements M, Lewis A, De Souza A, Zuniga A, Dawe M, Xiong Y, Clive D, Greiner R, Nazyrova A, Shaykhutdinov R, Li L, Vogel HJ, Forsythe I (2009) HMDB: a knowledgebase for the human metabolome. Nucleic Acids Res 37(Database issue):D603–D610. https://doi.org/10.1093/nar/gkn810CrossRefPubMed

19.

Lumbreras B, Porta M, Marquez S, Pollan M, Parker LA, Hernandez-Aguado I (2008) QUADOMICS: an adaptation of the quality assessment of diagnostic accuracy assessment (QUADAS) for the evaluation of the methodological quality of studies on the diagnostic accuracy of ‘-omics’-based technologies. Clin Biochem 41(16-17):1316–1325. https://doi.org/10.1016/j.clinbiochem.2008.06.018CrossRefPubMed

20.

Yu L, Qi H, An G, Bao J, Ma B, Zhu J, Ouyang G, Zhang P, Fan H, Zhang Q (2019) Association between metabolic profiles in urine and bone mineral density of pre- and postmenopausal Chinese women. Menopause 26(1):94–102CrossRefPubMed

21.

Miyamoto T, Hirayama A, Sato Y, Koboyashi T, Katsuyama E, Kanagawa H, Fujie A, Morita M, Watanabe R, Tando T, Miyamoto K, Tsuji T, Funayama A, Soga T, Tomita M, Nakamura M, Matsumoto M (2018) Metabolomics-based profiles predictive of low bone mass in menopausal women. Bone Rep 9:11–18. https://doi.org/10.1016/j.bonr.2018.06.004CrossRefPubMedPubMedCentral

22.

Liu L, Wen Y, Zhang L, Xu P, Liang X, Du Y, Li P, He A, Fan Q, Hao J (2018) Assessing the associations of blood metabolites with osteoporosis: a Mendelian randomization study. The Journal of Clinical Endocrinology & Metabolism 103(5):1850–1855CrossRef

23.

Long T, Hicks M, Yu HC, Biggs WH, Kirkness EF, Menni C, Zierer J, Small KS, Mangino M, Messier H, Brewerton S, Turpaz Y, Perkins BA, Evans AM, Miller LA, Guo L, Caskey CT, Schork NJ, Garner C, Spector TD, Venter JC, Telenti A (2017) Whole-genome sequencing identifies common-to-rare variants associated with human blood metabolites. Nat Genet 49(4):568–578. https://doi.org/10.1038/ng.3809CrossRefPubMed

24.

Ding KH, Cain M, Davis M, Bergson C, McGee-Lawrence M, Perkins C, Hardigan T, Shi X, Zhong Q, Xu J, Bollag WB, Hill W, Elsalanty M, Hunter M, Isales MC, Lopez P, Hamrick M, Isales CM (2018) Amino acids as signaling molecules modulating bone turnover. Bone 115:15–24. https://doi.org/10.1016/j.bone.2018.02.028CrossRefPubMedPubMedCentral

25.

Wallace TC, Frankenfeld CL (2017) Dietary protein intake above the current RDA and bone health: a systematic review and meta-analysis. J Am Coll Nutr 36(6):481–496. https://doi.org/10.1080/07315724.2017.1322924CrossRefPubMed

26.

Shams-White MM, Chung M, Du M, Fu Z, Insogna KL, Karlsen MC, LeBoff MS, Shapses SA, Sackey J, Wallace TC, Weaver CM (2017) Dietary protein and bone health: a systematic review and meta-analysis from the National Osteoporosis Foundation. Am J Clin Nutr 105(6):1528–1543. https://doi.org/10.3945/ajcn.116.145110CrossRefPubMed

27.

Su Y, Elshorbagy A, Turner C, Refsum H, Chan R, Kwok T (2019) Circulating amino acids are associated with bone mineral density decline and ten-year major osteoporotic fracture risk in older community-dwelling adults. Bone 129:115082. https://doi.org/10.1016/j.bone.2019.115082CrossRefPubMedPubMedCentral

28.

Conconi MT, Tommasini M, Muratori E, Parnigotto PP (2001) Essential amino acids increase the growth and alkaline phosphatase activity in osteoblasts cultured in vitro. Farmaco 56(10):755–761. https://doi.org/10.1016/s0014-827x(01)01126-0CrossRefPubMed

29.

Pallu S, Rochefort GY, Jaffre C, Refregiers M, Maurel DB, Benaitreau D, Lespessailles E, Jamme F, Chappard C, Benhamou CL (2012) Synchrotron ultraviolet microspectroscopy on rat cortical bone: involvement of tyrosine and tryptophan in the osteocyte and its environment. PLoS One 7(8):e43930. https://doi.org/10.1371/journal.pone.0043930CrossRefPubMedPubMedCentral

30.

Michalowska M, Znorko B, Kaminski T, Oksztulska-Kolanek E, Pawlak D (2015) New insights into tryptophan and its metabolites in the regulation of bone metabolism. Journal of Physiology and Pharmacology : an official journal of the Polish Physiological Society 66(6):779–791

31.

El Refaey M, Watkins CP, Kennedy EJ, Chang A, Zhong Q, Ding KH, Shi XM, Xu J, Bollag WB, Hill WD, Johnson M, Hunter M, Hamrick MW, Isales CM (2015) Oxidation of the aromatic amino acids tryptophan and tyrosine disrupts their anabolic effects on bone marrow mesenchymal stem cells. Mol Cell Endocrinol 410:87–96. https://doi.org/10.1016/j.mce.2015.01.034CrossRefPubMedPubMedCentral

32.

Ducy P, Karsenty G (2010) The two faces of serotonin in bone biology. J Cell Biol 191(1):7–13. https://doi.org/10.1083/jcb.201006123CrossRefPubMedPubMedCentral

33.

Amireault P, Sibon D, Cote F (2013) Life without peripheral serotonin: insights from tryptophan hydroxylase 1 knockout mice reveal the existence of paracrine/autocrine serotonergic networks. ACS Chem Neurosci 4(1):64–71. https://doi.org/10.1021/cn300154jCrossRefPubMed

34.

Kode A, Mosialou I, Silva BC, Rached MT, Zhou B, Wang J, Townes TM, Hen R, DePinho RA, Guo XE, Kousteni S (2012) FOXO1 orchestrates the bone-suppressing function of gut-derived serotonin. J Clin Invest 122(10):3490–3503. https://doi.org/10.1172/JCI64906CrossRefPubMedPubMedCentral

35.

Maria S, Witt-Enderby PA (2014) Melatonin effects on bone: potential use for the prevention and treatment for osteopenia, osteoporosis, and periodontal disease and for use in bone-grafting procedures. J Pineal Res 56(2):115–125. https://doi.org/10.1111/jpi.12116CrossRefPubMed

36.

Lee WC, Guntur AR, Long F, Rosen CJ (2017) Energy metabolism of the osteoblast: implications for osteoporosis. Endocr Rev 38(3):255–266. https://doi.org/10.1210/er.2017-00064CrossRefPubMedPubMedCentral

37.

Brown PM, Hutchison JD, Crockett JC (2011) Absence of glutamine supplementation prevents differentiation of murine calvarial osteoblasts to a mineralizing phenotype. Calcif Tissue Int 89(6):472–482. https://doi.org/10.1007/s00223-011-9537-6CrossRefPubMed

38.

Huang T, Liu R, Fu X, Yao D, Yang M, Liu Q, Lu WW, Wu C, Guan M (2017) Aging reduces an ERRalpha-directed mitochondrial glutaminase expression suppressing glutamine anaplerosis and osteogenic differentiation of mesenchymal stem cells. Stem Cells 35(2):411–424. https://doi.org/10.1002/stem.2470CrossRefPubMed

39.

Skerry TM, Genever PG (2001) Glutamate signalling in non-neuronal tissues. Trends Pharmacol Sci 22(4):174–181. https://doi.org/10.1016/s0165-6147(00)01642-4CrossRefPubMed

40.

da Silva RA, de Camargo Andrade AF, da Silva FG, Fernandes C, de Assis RIF, Ferreira MR, Andia DC, Zambuzzi WF (2018) The role of triiodothyronine hormone and mechanically-stressed endothelial cell paracrine signalling synergism in gene reprogramming during hBMSC-stimulated osteogenic phenotype in vitro. Mol Cell Endocrinol 478:151–167. https://doi.org/10.1016/j.mce.2018.08.008CrossRefPubMed

41.

Yuan LQ, Xie H, Luo XH, Wu XP, Zhou HD, Lu Y, Liao EY (2006) Taurine transporter is expressed in osteoblasts. Amino Acids 31(2):157–163. https://doi.org/10.1007/s00726-005-0313-7CrossRefPubMed

42.

Yuan LQ, Lu Y, Luo XH, Xie H, Wu XP, Liao EY (2007) Taurine promotes connective tissue growth factor (CTGF) expression in osteoblasts through the ERK signal pathway. Amino Acids 32(3):425–430. https://doi.org/10.1007/s00726-006-0380-4CrossRefPubMed

43.

Yuan LQ, Liu W, Cui RR, Wang D, Meng JC, Xie H, Wu XP, Zhou HD, Lu Y, Liao EY (2010) Taurine inhibits osteoclastogenesis through the taurine transporter. Amino Acids 39(1):89–99. https://doi.org/10.1007/s00726-009-0380-2CrossRefPubMed

44.

Choi MJ, Chang KJ, Lee JW, Jung YJ (2017) Beneficial function of taurine on bone metabolism in alcohol-fed OVX rat model. Adv Exp Med Biol 975(Pt 2):1059–1069. https://doi.org/10.1007/978-94-024-1079-2_84CrossRefPubMed

45.

Choi MJ (2009) Effects of taurine supplementation on bone mineral density in ovariectomized rats fed calcium deficient diet. Nutr Res Pract 3(2):108–113. https://doi.org/10.4162/nrp.2009.3.2.108CrossRefPubMedPubMedCentral

46.

Zaitseva OV, Shandrenko SG, Veliky MM (2015) Biochemical markers of bone collagen type I metabolism. Ukr. Biochem J 87(1):21–32. https://doi.org/10.15407/ubj87.01.021CrossRef

47.

Koike K, Li Y, Seo M, Sakurada I, Tezuka K, Uchikura K (2000) Free 4-hydroxyproline content in serum of bedridden aged people is elevated due to fracture. Biol Pharm Bull 23(1):101–103. https://doi.org/10.1248/bpb.23.101CrossRefPubMed

48.

Delport M, Maas S, van der Merwe SW, Laurens JB (2004) Quantitation of hydroxyproline in bone by gas chromatography-mass spectrometry. J Chromatogr B Anal Technol Biomed Life Sci 804(2):345–351. https://doi.org/10.1016/j.jchromb.2004.01.039CrossRef

49.

Engelen MP, Com G, Deutz NE (2014) Increased whole body hydroxyproline production as assessed by a new stable isotope technique is associated with hip and spine bone mineral loss in cystic fibrosis. Clin Nutr 33(6):1117–1121. https://doi.org/10.1016/j.clnu.2013.12.008CrossRefPubMed

50.

Atkinson W, Downer P, Lever M, Chambers ST, George PM (2007) Effects of orange juice and proline betaine on glycine betaine and homocysteine in healthy male subjects. Eur J Nutr 46(8):446–452. https://doi.org/10.1007/s00394-007-0684-5CrossRefPubMed

51.

Naylor K, Eastell R (2012) Bone turnover markers: use in osteoporosis. Nat Rev Rheumatol 8(7):379–389. https://doi.org/10.1038/nrrheum.2012.86CrossRefPubMed

52.

Aggarwal R, Bains K (2020) Protein, lysine and vitamin D: critical role in muscle and bone health. Crit Rev Food Sci Nutr:1–12. https://doi.org/10.1080/10408398.2020.1855101

53.

Civitelli R, Villareal DT, Agnusdei D, Nardi P, Avioli LV, Gennari C (1992) Dietary L-lysine and calcium metabolism in humans. Nutrition 8(6):400–405PubMed

54.

Fini M, Torricelli P, Giavaresi G, Carpi A, Nicolini A, Giardino R (2001) Effect of L-lysine and L-arginine on primary osteoblast cultures from normal and osteopenic rats. Biomed Pharmacother 55(4):213–220. https://doi.org/10.1016/s0753-3322(01)00054-3CrossRefPubMed

55.

Nakano M, Nakamura Y, Suzuki T, Miyazaki A, Takahashi J, Saito M, Shiraki M (2020) Pentosidine and carboxymethyl-lysine associate differently with prevalent osteoporotic vertebral fracture and various bone markers. Sci Rep 10(1):22090. https://doi.org/10.1038/s41598-020-78993-wCrossRefPubMedPubMedCentral

56.

Barzilay JI, Buzkova P, Zieman SJ, Kizer JR, Djousse L, Ix JH, Tracy RP, Siscovick DS, Cauley JA, Mukamal KJ (2014) Circulating levels of carboxy-methyl-lysine (CML) are associated with hip fracture risk: the Cardiovascular Health Study. J Bone Miner Res 29(5):1061–1066. https://doi.org/10.1002/jbmr.2123CrossRefPubMed

57.

Poiana C, Radoi V, Carsote M, Bilezikian JP (2013) New clues that may link osteoporosis to the circulating lipid profile. Bone Res 1(3):260–266. https://doi.org/10.4248/BR201303004CrossRefPubMedPubMedCentral

58.

Panahi N, Soltani A, Ghasem-Zadeh A, Shafiee G, Heshmat R, Razi F, Mehrdad N, Nabipour I, Larijani B, Ostovar A (2019) Associations between the lipid profile and the lumbar spine bone mineral density and trabecular bone score in elderly Iranian individuals participating in the Bushehr Elderly Health Program: a population-based study. Arch Osteoporos 14(1):52. https://doi.org/10.1007/s11657-019-0602-5CrossRefPubMed

59.

Almeida M, O'Brien CA (2013) Basic biology of skeletal aging: role of stress response pathways. J Gerontol A Biol Sci Med Sci 68(10):1197–1208. https://doi.org/10.1093/gerona/glt079CrossRefPubMedPubMedCentral

60.

Campos AM, Maciel E, Moreira AS, Sousa B, Melo T, Domingues P, Curado L, Antunes B, Domingues MR, Santos F (2016) Lipidomics of mesenchymal stromal cells: understanding the adaptation of phospholipid profile in response to pro-inflammatory cytokines. J Cell Physiol 231(5):1024–1032. https://doi.org/10.1002/jcp.25191CrossRefPubMed

61.

Tian L, Yu X (2015) Lipid metabolism disorders and bone dysfunction--interrelated and mutually regulated (review). Mol Med Rep 12(1):783–794. https://doi.org/10.3892/mmr.2015.3472CrossRefPubMedPubMedCentral

62.

Muruganandan S, Roman AA, Sinal CJ (2009) Adipocyte differentiation of bone marrow-derived mesenchymal stem cells: cross talk with the osteoblastogenic program. Cell Mol Life Sci 66(2):236–253. https://doi.org/10.1007/s00018-008-8429-zCrossRefPubMed

63.

Nuttall ME, Gimble JM (2004) Controlling the balance between osteoblastogenesis and adipogenesis and the consequent therapeutic implications. Curr Opin Pharmacol 4(3):290–294. https://doi.org/10.1016/j.coph.2004.03.002CrossRefPubMed

64.

Almeida M, Ambrogini E, Han L, Manolagas SC, Jilka RL (2009) Increased lipid oxidation causes oxidative stress, increased peroxisome proliferator-activated receptor-gamma expression, and diminished pro-osteogenic Wnt signaling in the skeleton. J Biol Chem 284(40):27438–27448. https://doi.org/10.1074/jbc.M109.023572CrossRefPubMedPubMedCentral

65.

Zhao JW, Gao ZL, Mei H, Li YL, Wang Y (2011) Differentiation of human mesenchymal stem cells: the potential mechanism for estrogen-induced preferential osteoblast versus adipocyte differentiation. Am J Med Sci 341(6):460–468. https://doi.org/10.1097/MAJ.0b013e31820865d5CrossRefPubMed

66.

Bays HE, Ballantyne CM, Kastelein JJ, Isaacsohn JL, Braeckman RA, Soni PN (2011) Eicosapentaenoic acid ethyl ester (AMR101) therapy in patients with very high triglyceride levels (from the Multi-center, plAcebo-controlled, Randomized, double-blINd, 12-week study with an open-label Extension [MARINE] trial). Am J Cardiol 108(5):682–690. https://doi.org/10.1016/j.amjcard.2011.04.015CrossRefPubMed

67.

Kim HH, Cho S, Lee S, Kim KH, Cho KH, Eun HC, Chung JH (2006) Photoprotective and anti-skin-aging effects of eicosapentaenoic acid in human skin in vivo. J Lipid Res 47(5):921–930. https://doi.org/10.1194/jlr.M500420-JLR200CrossRefPubMed

68.

Sengupta S, Muir JG, Gibson PR (2006) Does butyrate protect from colorectal cancer? J Gastroenterol Hepatol 21(1 Pt 2):209–218. https://doi.org/10.1111/j.1440-1746.2006.04213.xCrossRefPubMed

69.

Brown DG, Rao S, Weir TL, O’Malia J, Bazan M, Brown RJ, Ryan EP (2016) Metabolomics and metabolic pathway networks from human colorectal cancers, adjacent mucosa, and stool. Cancer Metab 4:11. https://doi.org/10.1186/s40170-016-0151-yCrossRefPubMedPubMedCentral

70.

Livshits G, Macgregor AJ, Gieger C, Malkin I, Moayyeri A, Grallert H, Emeny RT, Spector T, Kastenmuller G, Williams FM (2015) An omics investigation into chronic widespread musculoskeletal pain reveals epiandrosterone sulfate as a potential biomarker. Pain 156(10):1845–1851. https://doi.org/10.1097/j.pain.0000000000000200CrossRefPubMedPubMedCentral

71.

St-Pierre MV, Kullak-Ublick GA, Hagenbuch B, Meier PJ (2001) Transport of bile acids in hepatic and non-hepatic tissues. J Exp Biol 204(Pt 10):1673–1686CrossRefPubMed

72.

Davis RA, Miyake JH, Hui TY, Spann NJ (2002) Regulation of cholesterol-7alpha-hydroxylase: BAREly missing a SHP. J Lipid Res 43(4):533–543CrossRefPubMed

73.

Hanly R, Ryan N, Snelling H, Walker-Bone K, Dizdarevic S, Peters AM (2013) Association between bile acid turnover and osteoporosis in postmenopausal women. Nucl Med Commun 34(6):597–600. https://doi.org/10.1097/MNM.0b013e3283608993CrossRefPubMed

74.

Marchionatti A, Rivoira M, Rodriguez V, Perez A, Tolosa de Talamoni N (2018) Molecular mechanisms triggered by bile acids on intestinal Ca2+ absorption. Curr Med Chem 25(18):2122–2132. https://doi.org/10.2174/0929867324666171116125131CrossRefPubMed

75.

Zhao YX, Song YW, Zhang L, Zheng FJ, Wang XM, Zhuang XH, Wu F, Liu J (2020) Association between bile acid metabolism and bone mineral density in postmenopausal women. Clinics (Sao Paulo) 75:e1486. https://doi.org/10.6061/clinics/2020/e1486CrossRef

76.

Zhao C, Liang J, Yang Y, Yu M, Qu X (2017) The impact of glucagon-like peptide-1 on bone metabolism and its possible mechanisms. Front Endocrinol 8:98. https://doi.org/10.3389/fendo.2017.00098CrossRef

77.

Wu X, Li S, Xue P, Li Y (2017) Liraglutide, a glucagon-like peptide-1 receptor agonist, facilitates osteogenic proliferation and differentiation in MC3T3-E1 cells through phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT), extracellular signal-related kinase (ERK)1/2, and cAMP/protein kinase A (PKA) signaling pathways involving beta-catenin. Exp Cell Res 360(2):281–291. https://doi.org/10.1016/j.yexcr.2017.09.018CrossRefPubMed

78.

Colucci S, Mori G, Vaira S, Brunetti G, Greco G, Mancini L, Simone GM, Sardelli F, Koverech A, Zallone A, Grano M (2005) L-carnitine and isovaleryl L-carnitine fumarate positively affect human osteoblast proliferation and differentiation in vitro. Calcif Tissue Int 76(6):458–465. https://doi.org/10.1007/s00223-004-0147-4CrossRefPubMed

79.

Aubin I, Adams CP, Opsahl S, Septier D, Bishop CE, Auge N, Salvayre R, Negre-Salvayre A, Goldberg M, Guenet JL, Poirier C (2005) A deletion in the gene encoding sphingomyelin phosphodiesterase 3 (Smpd3) results in osteogenesis and dentinogenesis imperfecta in the mouse. Nat Genet 37(8):803–805. https://doi.org/10.1038/ng1603CrossRefPubMed

80.

Sims SM, Panupinthu N, Lapierre DM, Pereverzev A, Dixon SJ (2013) Lysophosphatidic acid: a potential mediator of osteoblast-osteoclast signaling in bone. Biochim Biophys Acta 1831(1):109–116. https://doi.org/10.1016/j.bbalip.2012.08.001CrossRefPubMed

81.

David M, Machuca-Gayet I, Kikuta J, Ottewell P, Mima F, Leblanc R, Bonnelye E, Ribeiro J, Holen I, Lopez Vales R, Jurdic P, Chun J, Clezardin P, Ishii M, Peyruchaud O (2014) Lysophosphatidic acid receptor type 1 (LPA1) plays a functional role in osteoclast differentiation and bone resorption activity. J Biol Chem 289(10):6551–6564. https://doi.org/10.1074/jbc.M113.533232CrossRefPubMedPubMedCentral

82.

Watanabe N, Zmijewski JW, Takabe W, Umezu-Goto M, Le Goffe C, Sekine A, Landar A, Watanabe A, Aoki J, Arai H, Kodama T, Murphy MP, Kalyanaraman R, Darley-Usmar VM, Noguchi N (2006) Activation of mitogen-activated protein kinases by lysophosphatidylcholine-induced mitochondrial reactive oxygen species generation in endothelial cells. Am J Pathol 168(5):1737–1748. https://doi.org/10.2353/ajpath.2006.050648CrossRefPubMedPubMedCentral

83.

Kwak HB, Lee SW, Li YJ, Kim YA, Han SY, Jhon GJ, Kim HH, Lee ZH (2004) Inhibition of osteoclast differentiation and bone resorption by a novel lysophosphatidylcholine derivative, SCOH. Biochem Pharmacol 67(7):1239–1248. https://doi.org/10.1016/j.bcp.2003.10.032CrossRefPubMed

84.

Jove M, Mate I, Naudi A, Mota-Martorell N, Portero-Otin M, De la Fuente M, Pamplona R (2016) Human aging is a metabolome-related matter of gender. J Gerontol A Biol Sci Med Sci 71(5):578–585. https://doi.org/10.1093/gerona/glv074CrossRefPubMed

85.

Hashimoto R, Miyamoto Y, Itoh S, Daida H, Okada T, Katoh Y (2019) Phorbol 12-myristate 13-acetate (PMA) suppresses high Ca(2+)-enhanced adipogenesis in bone marrow stromal cells. J Physiol Sci 69(5):741–748. https://doi.org/10.1007/s12576-019-00690-9CrossRefPubMed

86.

Sui L, Dong Y, Watanabe Y, Yamaguchi F, Hatano N, Tsukamoto I, Izumori K, Tokuda M (2005) The inhibitory effect and possible mechanisms of D-allose on cancer cell proliferation. Int J Oncol 27(4):907–912PubMed

87.

Sun X, Wei B, Peng Z, Fu Q, Wang C, Zhen J, Sun J (2019) Protective effects of Dipsacus asper polysaccharide on osteoporosis in vivo by regulating RANKL/RANK/OPG/VEGF and PI3K/Akt/eNOS pathway. Int J Biol Macromol 129:579–587. https://doi.org/10.1016/j.ijbiomac.2019.02.022CrossRefPubMed

88.

Liu H, Gu R, Zhu Y, Lian X, Wang S, Liu X, Ping Z, Liu Y, Zhou Y (2020) D-mannose attenuates bone loss in mice via Treg cell proliferation and gut microbiota-dependent anti-inflammatory effects. Ther Adv Chronic Dis 11:2040622320912661. https://doi.org/10.1177/2040622320912661CrossRefPubMedPubMedCentral

89.

Luukkonen J, Hilli M, Nakamura M, Ritamo I, Valmu L, Kauppinen K, Tuukkanen J, Lehenkari P (2019) Osteoclasts secrete osteopontin into resorption lacunae during bone resorption. Histochem Cell Biol 151(6):475–487. https://doi.org/10.1007/s00418-019-01770-yCrossRefPubMedPubMedCentral

90.

Andes FT, Adam S, Hahn M, Aust O, Frey S, Grueneboom A, Nitschke L, Schett G, Steffen U (2021) The human sialic acid-binding immunoglobulin-like lectin Siglec-9 and its murine homolog Siglec-E control osteoclast activity and bone resorption. Bone 143:115665. https://doi.org/10.1016/j.bone.2020.115665CrossRefPubMed

91.

Kameda Y, Takahata M, Mikuni S, Shimizu T, Hamano H, Angata T, Hatakeyama S, Kinjo M, Iwasaki N (2015) Siglec-15 is a potential therapeutic target for postmenopausal osteoporosis. Bone 71:217–226. https://doi.org/10.1016/j.bone.2014.10.027CrossRefPubMed

92.

Sato D, Takahata M, Ota M, Fukuda C, Hasegawa T, Yamamoto T, Amizuka N, Tsuda E, Okada A, Hiruma Y, Fujita R, Iwasaki N (2020) Siglec-15-targeting therapy protects against glucocorticoid-induced osteoporosis of growing skeleton in juvenile rats. Bone 135:115331. https://doi.org/10.1016/j.bone.2020.115331CrossRefPubMed

93.

Hung YT, Tikhonova MA, Ding SJ, Kao PF, Lan HH, Liao JM, Chen JH, Amstislavskaya TG, Ho YJ (2014) Effects of chronic treatment with diosgenin on bone loss in a D-galactose-induced aging rat model. Chin J Phys 57(3):121–127. https://doi.org/10.4077/CJP.2014.BAC199CrossRef

94.

Xu YK, Ng WG, Kaufman FR, Lobo RA, Donnell GN (1989) Galactose metabolism in human ovarian tissue. Pediatr Res 25(2):151–155. https://doi.org/10.1203/00006450-198902000-00015CrossRefPubMed

95.

Liu G, Shi F, Blas-Machado U, Yu R, Davis VL, Foster WG, Magoffin DA, Hughes CL (2006) Dietary galactose inhibits GDF-9 mediated follicular development in the rat ovary. Reprod Toxicol 21(1):26–33. https://doi.org/10.1016/j.reprotox.2005.07.001CrossRefPubMed

96.

Tardivel S, Fournier P, Dupuis Y, Nabarra B, Drueke T, Lacour B (1994) Stimulation of ileal calcium absorption by sorbitol, L-xylose, or creatine via a decrease in luminal sodium concentration: relation with concomitant changes in enterocyte energy metabolism. Calcif Tissue Int 54(4):304–311. https://doi.org/10.1007/BF00295955CrossRefPubMed

97.

Lacour B, Ohan J, Aznag A, Drueke TB (1995) Stimulating effects of sorbitol and L-xylose on rat ileal Ca transport in vitro. Miner Electrolyte Metab 21(6):391–397PubMed

98.

Notomi T, Karasaki I, Okazaki Y, Okimoto N, Kato Y, Ohura K, Noda M, Nakamura T, Suzuki M (2014) Insulinogenic sucrose+amino acid mixture ingestion immediately after resistance exercise has an anabolic effect on bone compared with non-insulinogenic fructose+amino acid mixture in growing rats. Bone 65:42–48. https://doi.org/10.1016/j.bone.2014.05.002CrossRefPubMed

99.

Yang Q, Zhang A-h, Miao J-h, Sun H, Han Y, Yan G-l, Wu F-f, Wang X-jJRA (2019) Metabolomics biotechnology, applications, and future trends: a systematic review. 9 (64):37245-37257. https://doi.org/10.1039/C9RA06697G

Titel: Metabolomic biomarkers of low BMD: a systematic review
verfasst von: N. Panahi
B. Arjmand
A. Ostovar
E. Kouhestani
R. Heshmat
A. Soltani
B. Larijani
Publikationsdatum: 26.07.2021
Verlag: Springer London
Erschienen in: Osteoporosis International / Ausgabe 12/2021
Print ISSN: 0937-941X
Elektronische ISSN: 1433-2965
DOI: https://doi.org/10.1007/s00198-021-06037-8

Arthropedia

Grundlagenwissen der Arthroskopie und Gelenkchirurgie. Erweitert durch Fallbeispiele, Videos und Abbildungen.
» Jetzt entdecken

Neu im Fachgebiet Orthopädie und Unfallchirurgie

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Arthroskopie kann Knieprothese nicht hinauszögern

25.04.2024 Gonarthrose Nachrichten

Ein arthroskopischer Eingriff bei Kniearthrose macht im Hinblick darauf, ob und wann ein Gelenkersatz fällig wird, offenbar keinen Unterschied.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Ärztliche Empathie hilft gegen Rückenschmerzen

23.04.2024 Leitsymptom Rückenschmerzen Nachrichten

Personen mit chronischen Rückenschmerzen, die von einfühlsamen Ärzten und Ärztinnen betreut werden, berichten über weniger Beschwerden und eine bessere Lebensqualität.

Update Orthopädie und Unfallchirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 12/2021

Comment on “Influence of glycemic control and hypoglycemia on the risk of fracture in patients with diabetes mellitus: a systematic review and meta-analysis of observational studies”

Excess mortality after hip fracture: fracture or pre-fall comorbidity?

Response to Letter from Prof Aspen, re. "Advanced 2D image processing technique to predict hip fracture risk in an older population based on single DXA scans"

Long-term risk of subsequent major osteoporotic fracture and hip fracture in men and women: a population-based observational study with a 25-year follow-up

Lifetime risks of hip fracture in patients with type 2 diabetic: Taiwan Diabetes Study